Gene expression signatures of breast cancer stem and progenitor cells do not exhibit features of Warburg metabolism by Nicole Gordon et al.
Gordon et al. Stem Cell Research & Therapy  (2015) 6:157 
DOI 10.1186/s13287-015-0153-7RESEARCH Open AccessGene expression signatures of breast
cancer stem and progenitor cells do not
exhibit features of Warburg metabolism
Nicole Gordon1†, Amy M. Skinner1†, Rodney F. Pommier1, Robynn V. Schillace1, Steven O’Neill1,
Jennifer L. Peckham1, Patrick Muller1, Mary E. Condron1, Cory Donovan1, Arpana Naik1, Juliana Hansen2
and SuEllen J. Pommier1*Abstract
Introduction: Cancers are believed to adapt to continual changes in glucose and oxygen availability by relying
almost exclusively on glycolytic metabolism for energy (i.e. the Warburg effect). The process by which breast cancers
sustain growth in avascular tissue is thought to be mediated via aberrant hypoxia response with ensuing shifts in
glycolytic metabolism. Given their role in initiating and perpetuating tumors, we sought to determine whether
breast cancer stem and progenitor cells play an instrumental role in this adaptive metabolic response.
Methods: Breast cancer stem/progenitor cells were isolated from invasive ductal carcinomas, and benign stem cells
(SC) were isolated from reduction mammoplasty tissues. Relative expression of 33 genes involved in hypoxia and
glucose metabolism was evaluated in flow cytometrically isolated stem and progenitor cell populations. Significance
between cohorts and cell populations was determined using Student’s 2-tailed t test.
Results: While benign stem/progenitor cells exhibited few significant inter-group differences in expression of genes
involved in hypoxia regulation or glucose metabolism, breast cancer stem/progenitor cells demonstrated significant
inter-group variability. Breast cancer stem/progenitor cells adapted to microenvironments through changes in
stem cell numbers and transcription of glycolytic genes. One of four breast cancer stem/progenitor cells
subpopulations exhibited an aerobic glycolysis gene expression signature. This subpopulation comprises the
majority of the tumor and therefore best reflects invasive ductal carcinoma tumor biology. Although PI3K/AKT
mutations are associated with increased proliferation of breast cancer cells, mutations in breast cancer stem/progenitor
cells subpopulations did not correlate with changes in metabolic gene expression.
Conclusions: The adaptive capacity of breast cancer stem/progenitor cells may enable tumors to survive variable
conditions encountered during progressive stages of cancer growth.Introduction
Breast cancer is the second most common malignancy
diagnosed in the world and the second leading cause of
cancer death among women [1]. To date, there is no
cure for recurrent or metastatic disease, which remains
the primary cause of death for women diagnosed with
breast cancer. Elucidating mechanisms that underlie the* Correspondence: pommiers@ohsu.edu
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Early biochemical studies revealed that cancer cells rap-
idly increase cellular proliferation by utilizing aberrant en-
ergy pathways. Instead of completing the standard steps in
glucose metabolism of glycolysis, Krebs cycle, and oxida-
tive phosphorylation, cancer cells rely heavily on glycoly-
sis, and produce a considerable amount of lactate in the
presence of adequate oxygen, a phenomenon known as
the Warburg effect [2]. However, while some reports as-
sert that cancer cells upregulate glycolysis as an adaptive
response to changing oxygen requirements as the tumorle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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reflection of rapidly dividing cells [3–5]. Some believe that
rare populations of stem-like cells reside in benign adult
tissues and routinely perform Warburg metabolism, and
that these cells maintain this metabolic feature throughout
carcinogenic transformation [6–8]. Other reports believe
that a symbiotic or “reverse Warburg” relationship exists
between glycolytic tumor stromal cells, which generate
glycolytic byproducts, and nonglycolytic neighboring cells,
which utilize these byproducts for energy [9, 10]. Still
other reports claim that cancer cells shift to glycolytic me-
tabolism as a result of specific oncogenic or tumor sup-
pressor mutations [11, 12]. Differentiating between these
models has important implications for the diagnosis, man-
agement, and treatment of cancer patients.
Recent studies have implicated cancer stem cells (CSCs)
in the heterogeneity, viability, propagation, and recurrence
of tumors [13]. First identified in hematologic cancer,
CSCs have since been identified in many solid tumors, in-
cluding breast cancer. Although breast tumors are com-
prised of less than 5 % breast cancer stem/progenitor cells
(BCSCs), specific cellular subpopulations can be prospect-
ively isolated from human tumors and efficiently give rise
to phenotypically similar tumors in immunodeficient mice
[14]. Despite the fact that CSCs are recognized as an es-
sential component of tumors, the adaptive mechanisms of
malignant transformation employed by BCSCs are not
thoroughly understood.
We hypothesized that BCSCs modulate tumor fitness
via influencing the behavior of the more differentiated
cell components of the tumor. The BCSCs may be meta-
bolically reprogramming nonstem breast tumor cells to-
ward a glycolytic state. To test this hypothesis, BCSCs
from invasive ductal carcinoma (IDC) tissues and benign
breast stem/progenitor cells (SCs) from reduction mam-
moplasty tissues were flow cytometrically isolated and an-
alyzed for differences in expression of 33 genes involved
in hypoxia response and glucose metabolism.Materials and methods
Cell culture
Human HCC1937, HCC1806, MCF7, and MCF10A cells
were acquired from ATCC (Manassas, VA, USA). Cells were
cultured at subconfluence, utilized at low passage level, and
maintained according to ATCC recommendations.Patient selection and surgical specimens
After obtaining Oregon Health & Science Institutional
Review Board (OHSU IRB) approval and patient consent,
tissues for this study were collected from 15 patients with
IDC and 11 patients who underwent reduction mammo-
plasty. All procedures were followed in accordance with the
ethical standards of the OHSU IRB and the Declaration ofHelsinki. All tissues were subject to pathologic evaluation
and confirmation of diagnosis.
Isolation of cell populations
Fresh breast tissue was obtained from pathology, finely
minced, and immediately cryopreserved in liquid nitrogen.
Upon preparation for analysis, tissue specimens were thawed,
and digested overnight in a Pyrex (nonadherent) trypsinizing
flask with mammary epithelial cell-specific medium contain-
ing collagenase/hyaluronidase (Epicult; StemCell Technolo-
gies, Vancouver, BC, Canada). Cells were agitated on a rotary
shaker overnight, with incubation at 37 °C. The following day,
all cells were washed with phosphate-buffered saline + 2 %
fetal bovine serum, pelleted, and digested with DNase and
trypsin. SCs and BCSCs were immediately isolated (without
culture) via fluorescence-activated cell sorting (FACS) using a
BD Influx or BD Vantage sorter (BD Biosciences, San Jose,
CA, USA) and CellQuest software (San Jose, CA, USA). Anti-
bodies were obtained from BD Biosciences unless otherwise
stated. Lineage committed endothelial (CD31-FITC+),
lymphocyte (CD45-FITC+), and nonviable (PI+) populations
were removed, and CD49f-APC (BD Bioscience, San Jose,
CA, USA) and CD24-PE were used to sort cells into the
following populations: CD49fhiCD24hi, CD49flowCD24hi,
CD49fhiCD24low, and CD49flowCD24low. Additional popu-
lation statistics were collected based on gating with
CD44-PECy7+ and EpCAM-brilliant violet+ (BioLegend,
San Diego, CA, USA).
Hypoxia/normoxia cell culture
Equal numbers of subconfluent cells (T47D, MCF7,
HCC1937, HCC1806, and MCF10A) were plated in six-
well tissue culture plates in corresponding media. Add-
itionally, a subset of cells digested from benign tissue and
cancer specimens were cultured at 37 °C overnight in hyp-
oxic (1 % oxygen) or normoxic (21 % oxygen) conditions
prior to FACS. Hypoxia was administered by flushing a
gas-impermeable chamber (Billups-Rothenberg, Inc., Del
Mar, CA, USA) with 1 % oxygen. All cells (suspension and
adherent) were harvested, and were then stained and
sorted into corresponding BCSC or SC subpopulations.
TaqMan low-density array
RNA was extracted from whole tissue or sorted cell pop-
ulations using a Qiagen RNeasy kit (Germantown, MD,
USA), and reverse transcribed using a Superscript III
First-Strand Synthesis System with random hexamer
primers (Life Technologies, Waltham, MA, USA). Expres-
sion of 33 hypoxia and glucose metabolism-related genes
(HypoxyGluMet) was measured by quantitative RT-PCR
via a low-density array (TLDA; Life Technologies) micro-
fluidic card according to the manufacturer’s protocol.
Differences in gene expression were determined using Ex-
pression Suite v1.0.2 software (Life Technology, Waltham,
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scores were reassigned a delta Ct value of 40 if the amplifi-
cation score for the endogenous gene and the gene of inter-
est (18S) was ≥0.80. Gene Card 1 assayed the following
genes: ALDOA [UniGene:Hs.513490], AKT1 [UniGe-
ne:Hs.525622], ENO1 [UniGene:Hs.517145], EPO [UniGe-
ne:Hs.2303], GSK3B [UniGene:Hs.445733], HIF1A [597216],
HMOX1 [UniGene:Hs.517581], LDHA [UniGene:Hs.5795],
LOX [UniGene:Hs.102267], PDHA1 [UniGene:Hs.530331],
PFKL [UniGene:Hs.255093], PGK1 [UniGene:Hs.78771],
PKLR [UniGene:Hs.95990], PKM2 [UniGene:Hs.534770],
PLOD2 [UniGene:Hs.477866], SLC2A1 [UniGene:Hs.
473721], TFRC [UniGene:Hs.529618], and VEGFA [Uni-
Gene:Hs.73793]. Gene Card 2 assayed the following genes:
EGR1 [UniGene:Hs.326035], G6PD [UniGene:Hs.461047],
GAPDH [UniGene:Hs.544577], HK2 [UniGene:Hs.406266],
SLC16A3 [UniGene:Hs.500761], NGFR [UniGene:Hs.415768],
PC [UniGene:Hs.89890], PCK2 [UniGene:Hs.75812], PDK1
[UniGene:Hs.470633], PPARGC1A [UniGene:Hs.527078],
SLC2A3 [UniGene:Hs.419240], SLC9A1 [UniGene:Hs.469116],
SOD2 [UniGene:Hs.487046], TALDO1 [UniGene:Hs.438678],
and TKT [UniGene:Hs.89643].
Statistical analysis
Unless otherwise stated, statistical significance was de-
termined by Student’s unpaired t test with two-tailed
distribution.
Results
Breast cancer cell lines convert to glycolytic metabolism
following hypoxia
To better understand the respective roles of hypoxia
and glycolysis in driving the malignant transformation
of BCSCs, a novel gene expression array (HypoxyGlu-
Met) was designed. Hypoxia inducible factor-1α (HIF-
1α) is a transcription factor orchestrating cellular sur-
vival in response to hypoxic conditions, including in-
duction of several glycolysis genes. Glycolytic and
nonglycolytic HIF-1α gene targets were examined in the
array (Fig. 1a). To validate the assay, the metabolic pro-
file of well-characterized breast cancer cell lines and
MCF10A mammary epithelial cells was examined after
24 hours of culture under normoxic (21 %) or hypoxic
(1 %) conditions. Consistent with published observa-
tions, gene expression of HIF-1α remained relatively un-
affected (i.e., <2-fold difference) by hypoxic culture
conditions in each of the cell lines examined, while HIF-
1α inducible genes were affected by hypoxia (Fig. 1b)
[15]. Notably, in response to hypoxic conditions, the
relative expression of lysyl oxidase (LOX) significantly
increased 25-fold and 350-fold in T47D and MCF7 cell
lines, respectively (p <0.0001, Fig. 1b). The relative ex-
pression of vascular endothelial growth factor A
(VEGFA) in hypoxia-cultured cells was also significantlyincreased in four of five of the cell lines (p ≤0.005), com-
pared with normoxic-cultured controls. Most of the cell
lines demonstrated a significant change in relative expres-
sion of each gene target induced by HIF-1α in response to
hypoxic conditions. Although the array examined expres-
sion of 33 genes, only genes exhibiting statistical signifi-
cance in at least one cell line are shown in each figure. See
Materials and methods for a complete list of the genes
examined.
To further validate the HypoxyGluMet array, normoxic
or hypoxic-cultured breast cancer cell lines and MCF10A
mammary epithelial cells were evaluated for changes in
expression of HIF-1α-induced glycolytic genes. Expression
of the glucose transporter 3 gene (SLC2A3), which is
translated into glucose transporter protein GLUT3, was
most significantly augmented in response to hypoxic con-
ditions, with a 22-fold to 62-fold relative increase ob-
served in MCF7 and T47D cells, respectively (p ≤0.0016,
Fig. 1b). Observation of significantly elevated expression
of the majority of HIF-1α-dependent glycolytic gene tar-
gets with concurrent divergent patterns in expression of
HIF-1α-independent glycolytic gene targets in each of the
hypoxia treated cell lines supports the validity of employ-
ing the HypoxGlutMet array to elucidate the metabolic
profile of BCSCs.
HIF-1α gene targets are overexpressed in fresh IDC
specimens
Based on reports of increased glyceraldehyde-3-phosphate
dehydrogenase, pyruvate kinase, and lactate dehydrogenase
in breast carcinomas, we hypothesized that glycolytic me-
tabolism genes would be increased in primary breast cancer
specimens [16–18]. Indeed, when gene expression analysis
was conducted on fresh surgical specimens, the Hypoxy-
GluMet array revealed that breast tumors exhibited a 2.5-
fold increase in expression of HIF-1α compared with
benign tissues (Fig. 2a). Significant increases were also
observed in expression of HIF-1α targets, heme oxygenase
1 (HMOX1; fourfold increase, p = 0.003) and LOX (2.8-fold
increase, p = 0.005). Several HIF-1α-inducible glycolytic
genes were overexpressed in breast tumors, although most
of these increases did not reach statistical significance
(Fig. 2b). Pyruvate kinase isozyme M2 (PKM2) was the
exception, in that it was expressed significantly higher
(twofold, p = 0.004) in breast tumors compared with
benign tissues.
Glycolytic genes not known to be dependent upon
HIF-1α induction demonstrated similar expression
between breast cancer specimens and benign tissues
(Fig. 2c). Expression of the mitochondrial gene superoxide
dismutase 2 (SOD2) was included in the HypoxyGluMet
array because SOD2 is expressed in mitochondria where
reactive oxygen species (ROS) are generated in response
to hypoxia or respiratory bursts of the electron transport
Fig. 1 Validation of the HypoxyGluMet gene expression array in breast cancer cell lines. a Overview of HIF-1-gene targets (red), HIF-1α-dependent
glycolytic gene targets (purple), and HIF-1α-independent glycolytic gene targets (blue) assayed by the HypoxyGluMet array. For clarity and
consistency, this color scheme is employed in each figure. Gene symbols are shown in parentheses. b Breast cancer cell lines T47D, MCF7, HCC1806,
HCC1937, and benign epithelial MCF10A cells were cultured overnight under hypoxic or normoxic conditions. RNA was isolated, cDNA was
synthesized, and relative expression of HIF-1 nonglycolytic gene targets (red columns), HIF-1-dependent glycolytic gene targets (purple columns), and
HIF-1-independent glycolytic gene targets (blue columns) was quantified via the HypoxyGluMet array. Data shown are the mean of two independent
experiments; individual samples were performed in duplicate (Gene Card 2, see Materials and methods) or in triplicate (Gene Card 1). Significance was
determined using Student’s paired t test on ΔCt values, with two-tailed distribution. Error bars were calculated as the standard error of the
mean (SEM). *p ≤0.05, **p ≤0.01
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Fig. 2 Relative expression of glycolytic genes in breast tumor versus benign tissue. The HypoxyGluMet array was employed on tumors (n = 15)
and benign tissues (n = 11) to determine relative expression of a HIF-1 and HIF-1-dependent nonglycolytic genes, b HIF-1α-dependent glycolytic
genes, and c HIF-1α-independent glycolytic genes. Average gene expression in tumor tissues is shown relative to average expression in benign
tissues. Error bars represent the 95 % confidence interval. *p ≤0.05, **p ≤0.01
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decreased SOD2 expression in many cancers, we observed
threefold lower expression of SOD2 in cancer specimens
compared with benign breast tissue (p = 0.03, Fig. 2c).
BCSCs and SCs exhibit distinctive metabolic profiles
We have previously isolated and characterized stem
and progenitor cells from human breast tissue by employ-
ing cell surface markers CD49f (integrin α6) and CD24
[22–26]. Abundant heterogeneity exists between cell pop-
ulations, breast cancers, and patients, so the definitive
immunophenotype of breast CSCs has not yet been recon-
ciled; however, other studies in the CSC field have simi-
larly employed these markers to isolate and characterize
human breast stem and progenitor cells [27–33].
Having examined stem and progenitor cell quality and
quantity in CD49f and CD24 variably expressing popula-
tions using a TaqMan Human Stem Cell Pluripotency
Array Micro Fluidic Card and surrogate mammosphere
assays in previous work [23], we herein sought to dir-
ectly compare metabolic profiles of these stem and
progenitor-like cell subpopulations between breast can-
cer specimens and benign breast tissues. BCSCs from 15
IDC tissues and SCs from 11 reduction mammoplasty
tissues were isolated via FACS to exclude lineage-
committed populations (CD31 and CD45) and collect
CD49f and CD24 cells. Subpopulations expressing
CD49fhiCD24low, CD49fhiCD24hi, CD49flowCD24hi, and
CD49flowCD24low were isolated (Fig. 3a, b). Consistent
with our previous observations, we observed substantial
quantitative differences in the number of cells in each
population; although we observed variability between
samples, the percentages of BCSCs isolated from tumors
did not statistically differ from the percentages of SCs
isolated from benign tissues (Fig. 3c) [23].
The HypoxyGluMet array was employed to characterize
each cellular subpopulation. Contrary to the expectationthat HIF-1α would be activated by glycolytic metabolites
in cancer cells [34], we observed that CD49fhi BCSCs
(CD49fhiCD24hi, CD49fhiCD24low) demonstrated reduced
expression of HIF-1α gene targets as well as of HIF-1α-
inducible glycolytic genes compared with CD49fhi SCs
(Fig. 3d, e). Specifically, significant decreases in expres-
sion of HMOX1 (−50-fold, p = 0.03) and aldolase
(ALDOA; −500-fold, p = 0.01) were observed in
CD49fhiCD24hi cancer cells compared with benign cell
counterparts. Similarly, CD49fhiCD24low tumor cells
exhibited significantly lower expression of EGR1 (−20-fold,
p = 0.02), glucose transporter 3 (SLC2A3; −50-fold,
p = 0.03), and GAPDH (−100-fold, p = 0.01) than benign
cell counterparts.
There were few differences in HypoxyGluMet gene
expression profiles between subpopulations of CD49flow
cells (CD49flowCD24hi, CD49flowCD24low) isolated
from cancer versus benign breast tissue. However,
CD49flowCD24low BCSCs exhibited significantly re-
duced expression of PKLR (−100-fold, p = 0.01) com-
pared with SC counterparts (Fig. 3f). There were no
significant differences detected in gene expression between
CD49flowCD24hi BCSCs versus SC counterparts (Fig. 3g).
Glycolytic metabolism gene transcripts are lower in
BCSCs than in tumor of origin
When compared with corresponding tissue from which
stem cells were obtained, SCs exhibited few significant in-
tergroup differences in HypoxyGluMet gene expression
(Fig. 4a–d). One exception, however, is expression of
HMOX1 in CD49fhi benign subpopulations, which was
augmented 12-fold (p = 0.005) and 69-fold (p = 0.0006) in
CD49fhiCD24hi and CD49fhiCD24low SC populations rela-
tive to tissue, respectively.
In contrast, BCSCs demonstrated significant inter-
group variability. Three of four BCSC subpopulations
exhibited lower overall expression of glucose metabolism
Fig. 3 BCSCs exhibit decreased expression of several metabolic genes relative to SCs. a, b Representative FACS plots of subpopulations isolated from
a benign or bmalignant breast tissue. c Average percentage of total CD45−, CD31− (lin–) stem, and progenitor subpopulations isolated from benign
(gray, n = 15) or malignant (green, n = 11) breast tissue. Error bars represent standard deviation of the mean. d–g Gene expression was determined for
subpopulations of BCSCs (n = 13) relative to SC counterparts (n = 9). HIF-1α and nonglycolytic HIF-1α-inducible gene targets (red), HIF-1α-dependent
glycolytic gene targets (purple), and HIF-1α-independent glycolytic gene targets (blue) are color coded. Error bars represent the 95 % confidence interval
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CD49fhiCD24hi subpopulation most significantly differed
from the tumor of origin, with reduced expression
observed in the majority of HIF-1α inducible glycolytic
genes, as well as HIF-1α-independent glycolytic genes
(Fig. 4e). Although the CD49flowCD24low BCSC subpopu-
lation exhibited nearly twofold increased expression of
HIF-1α (p = 0.02) compared with the tumor of origin,
with corresponding increases in expression of downstream
HIF-1α-dependent genes (LOX, VEGFA), we did notobserve significant differences in the expression of HIF-
1α-dependent glucose metabolism genes (Fig 4h). This
subpopulation exhibited gene expression most similar to
that of unfractionated tumor of origin.
BCSCs do not increase glycolytic gene expression in
response to hypoxia
To determine how acute changes in oxygen availability
affect HIF-1α-dependent gene expression and cellular me-
tabolism in primary BCSCs, single cell suspensions were
Fig. 4 (See legend on next page.)
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Fig. 4 Metabolic signature of BCSC and SC subpopulations. a–d Gene expression in subpopulations of SCs was determined relative to corresponding
benign tissue (n = 10). e–h Gene expression in subpopulations of malignant BCSCs was determined relative to corresponding tumor (n = 11). HIF-1α
and nonglycolytic HIF-1α-inducible gene targets (red), HIF-1α-dependent glycolytic gene targets (purple), and HIF-1α-independent glycolytic
gene targets (blue) are color coded. Significance was determined by Student’s paired t test with two-tailed distribution. Error bars represent
the 95 % confidence interval. *p ≤0.05, **p ≤0.01 BCSC breast cancer stem/progenitor cell, SC benign breast stem/progenitor cell
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tured overnight under hypoxic or normoxic conditions
(Fig. 5a). The following day, all cells (in suspension or at-
tached) were sorted into BCSC subpopulations. The hyalur-
onan receptor, CD44, is implicated in cancer cell growth
and proliferation, and is induced by hypoxia in triple-
negative breast cancer [35–37]. Expression of CD44 was
therefore assessed in each BCSC subpopulation. There was
a 1.5-fold increase in the proportion of cells coexpressing
CD44+ and BCSC markers following overnight culture in
hypoxic versus normoxic conditions (Fig. 5b). Similar amp-
lification of SCs expressing CD44 following hypoxia was
observed but was not significant.
To further investigate how BCSCs respond to hypoxia,
subpopulations were isolated from hypoxia-exposed and
normoxia-exposed cells via FACS, RNA was isolated
from each population, and gene expression was quanti-
fied using the HypoxGluMet array. Benign specimens
were treated and isolated with similar approach. In SCs,
there were few significant differences in metabolic gene
expression following hypoxia culture (Fig. 5c). Genes
encoding glucose transporter 3 (SLC2A3), pyruvate de-
hydrogenase kinase (PDK), and peroxisome proliferator-
activated receptor gamma coactivator 1-α (PPARGC1A)
were augmented nearly threefold in CD49fhiCD24hi cells
(Fig. 5c). In hypoxia-cultured BCSCs, the CD49flowCD24hi
subpopulation demonstrated a threefold increase in the
gene encoding vascular endothelial growth factor (VEGF),
and was the only significant difference observed (Fig. 5d).
There were no significant differences observed in
CD49flowCD24low subpopulations isolated from benign or
malignant specimens.
No correlation with PIK3CA mutation or hormone
receptor status
When wild-type cells encounter hypoxic conditions,
phosphatidylinositol 3-kinase (PI3K) phosphorylates Akt,
resulting in inactivation of glycogen synthase kinase
GSK-3 and subsequent decrease in cellular metabolism
and proliferation. If the PI3K/AKT pathway is impaired,
as frequently occurs in cancer, cells are subject to in-
creased glycolysis and proliferation despite low oxygen
availability [38–40]. We previously described the muta-
tional profile of 30 IDC specimens (including all 15
tumors from this study) and corresponding BCSC
subpopulations using Sequenome Mass ARRAY analysis
[22]. Of the 15 tumors subject to glycolytic metabolicprofiling, nine patients were identified with tumor and/
or BCSC mutations in the catalytic subunit encoding the
PI3K enzyme PIK3CA. Examination of whether the
PI3K/AKT mutations correlated with changes in tumor
or BCSC metabolic gene expression observed in the
HypoxyGluMet array did not identify any predictive dif-
ferences (data not shown).
In a previous study that utilized immunohistochemis-
try to characterize the metabolic phenotype of 740
breast cancers, a greater association of Warburg metab-
olism was observed in breast cancers that lack expres-
sion of hormone receptors (estrogen receptor (ER−),
progesterone receptor (PR−), and human epidermal
growth factor 2 (HER2−)) [41]. Similarly, another group
performed a proteomic analysis on breast tumors and
observed augmented glycolytic protein content in ERα−
tumors relative to ERα+ tumors [42]. We similarly
assessed whether changes in BCSC gene expression we
observed correlated with ER status but did not observe
any significant associations (data not shown). There
were also no notable correlations between gene expres-
sion patterns and size of tumor, receptor status (e.g., ER,
PR, or Her2/neu), or tumor stage (data not shown).
Discussion
In benign tissues, the principle means of cellular adapta-
tion to low oxygen availability is via HIF-1α-mediated
induction of several genes that act in concert to decrease
cell proliferation, decrease the rate of glycolysis, and in-
crease angiogenesis in response to increased demand for
oxygen [40]. Cancer cells often usurp the HIF-1 pathway
to facilitate cell growth, survival, and angiogenesis as
rapidly growing cells continually deplete available oxy-
gen from tissue. Byproducts of glucose metabolism, such
as pyruvate and lactate, stabilize HIF-1α, and further in-
duce other HIF-1α-responsive genes [34]. Given their
significant role in propagating and perpetuating tumors,
we sought to determine whether BCSCs adapt to a
hypoxic microenvironment by adopting a glycolytic
(i.e., Warburg-like) state.
We designed a HypoxyGluMet gene expression array
to survey the expression of genes activated by HIF-1α as
well as genes involved in glucose metabolism. We
employed the array to compare gene expression profiles
between breast cancers and benign breast tissues and
determined that there were few significant differences
between tissues. Increased expression of PKM2 was
Fig. 5 Differential response of BCSCs and SCs to hypoxia. a Schematic of experimental design. b Breast cancer (n = 2) and benign tissue
(n = 2) specimens were enzymatically digested into single cell suspension. Cells were divided equally and cultured overnight in normoxic
or hypoxic conditions. BCSC and SC populations (CD49f+CD24+, CD49f+CD24−, CD49f−CD24+, CD49f−CD24−) were immediately isolated by
FACS analysis of all cells (adherent and suspension) the following day, and gene expression was determined via the HypoxyGluMet array.
Error bars represent of two samples, run in duplicate (Gene Card 1) or in triplicate (Gene Card 2). Significance was determined by Student’s paired t
test with two-tailed distribution. **p <0.01. c, d Gene expression of HIF-1α-dependent genes (red), HIF-1α-dependent glycolytic genes
(purple), and HIF-1α-independent glycolytic genes (blue) was determined in hypoxic-treated relative to normoxic-treated c benign and
d tumor specimens. Error bars (present in all panels but possibly too small to visualize) represent standard deviation of the mean. Significance
was determined by Student’s paired t test with two-tailed distribution. *p ≤0.05. BCSC breast cancer stem/progenitor cell, SC benign breast
stem/progenitor cell
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form is only expressed in cancer cells, stem cells, or em-
bryonic stem cells [43]. On the contrary, when gene
expression profiles of BCSC subpopulations were directly
compared with profiles of SC counterparts, we observed
significantly greater differences (i.e., up to 1000-fold) in
gene expression in three of four subpopulations. The
population most divergent from the benign counterpart
was the CD49fhiCD24low subpopulation, which demon-
strated reduced expression in the majority of assayedtranscripts. The CD49flowCD24hi subpopulation did not
exhibit any statistically significant differences in profiles. It
is possible that stem cell hierarchy played a role in the
profile differences observed between SC and BCSC popu-
lations, because considerable differences in glycolytic
metabolism have been observed and attributed to CSC
hierarchy in several breast cancer cell lines [44].
Somatic stem cells, such as long-term repopulating
hematopoietic stem cells (LT-HSC), neural stem cells,
and mesenchymal stem cells maintain quiescence by
Gordon et al. Stem Cell Research & Therapy  (2015) 6:157 Page 10 of 12inhabiting a hypoxic niche to impart stringent control
of HIF-1α, and utilizing ROS signaling to progress to a
proliferative or differentiated state [45]. As HIF-1α is
active in quiescent stem cells and induces expression of
several glycolytic genes, somatic stem cells accordingly
exhibit a proglycolytic phenotype. Our data reveal that
SCs similarly exhibit proglycolytic traits, as expression
of several HIF-1α-dependent genes (glycocytic and
nonglycocytic) was increased relative to corresponding
tissue. SCs demonstrating features of glycolytic metab-
olism is further supported by increased expression of
glucose transporter 1 and/or 3 (SLC2A1, SLC2A3) in
each of the SC subpopulations relative to correspond-
ing tissue.
Compared with the proglycolytic phenotype observed in
SCs, our data revealed a considerably different metabolic
profile in BCSCs. Expression of glucose transporters was
decreased in three of four BCSC subpopulations relative
to tumor, and expression of the glycolytic rate-limiting en-
zyme phosphofructokinase (PFKL) was decreased in all
BCSC subpopulations. Moreover, transcripts of HIF-1α
and corresponding gene targets (glycocytic and nonglyco-
cytic) were reduced in three of four BCSC subpopula-
tions relative to tumor. These results oppose the model
of a classic proglycocytic phenotype. Highlighting the
heterogeneous nature of tumors, the CD49flowCD24low
cells comprised a distinctive BCSC population. These
cells displayed augmented expression of HIF-1α and
HIF-1α-inducible nonglycocytic targets, along with
minor increases in the expression of glucose trans-
porters SLC2A1 and SLC2A3. This subpopulation exhib-
ited a gene expression profile most similar to the tumor of
origin, which may be due to overrepresentation of these
cells within the tumor [23]. In contrast to other BCSC
subsets, the CD49flowCD24low cells displayed features
more consistent with classic Warburg metabolism.
Recent studies in tumor–microenvironment interac-
tions describe a reverse Warburg effect in which glyco-
lytic stromal cells nourish nonglycolytic tumor cells with
byproducts of glycolytic metabolism: lactic acid and
ketones [9, 10]. A comprehensive metabolic analysis of
nearly 1000 breast tumors revealed that the reverse
Warburg phenomenon is most commonly associated
with nonaggressive luminal A tumors [41]. Similarly, we
observed that a reverse Warburg phenomenon occurs
between complimentary phenotypes of glycocytic and
nonglycocytic BCSC subsets; however, we did not ob-
serve an association between the metabolic profile and
hormone status. Discrepancies between that study and
ours may be attributed to the comprehensiveness of
metabolic targets assayed in our array, as well as our
smaller patient cohort. Additional dissimilarities exist
between cell populations examined (BCSCs versus non-
specific stromal and tumor cells).Cells with CSC characteristics are enriched in breast
cancer cell lines following repeated exposure to hypoxic
conditions [46]. Although HIF-1α and corresponding in-
ducible targets are lower in BCSCs relative to tumor at
baseline, CD49fhiCD24hi and CD49flowCD24hi cell types
expressed higher levels of these transcripts following ex-
posure to hypoxia, as expected. In addition, expression
of glucose transporter SLC2A1 was slightly increased in
three of four subpopulations. It is recognized that the
magnitude of increase was not significant in the majority
of targets assessed. However, when the metabolic profile
of hypoxia/normoxia-treated SCs was compared with
the profile of hypoxia/normoxia-treated mature popula-
tions (CD49fhiCD24hi and CD49flowCD24hi), substantial
differences covering several orders of magnitude were
discerned. These data suggest that although under nor-
mal conditions BCSCs may not exhibit classic Warburg
metabolism, in hypoxic conditions BCSCs can modulate
tumor fitness via changes in stem cell numbers and
metabolic reprogramming of nonstem breast tumor cells
toward a glycolytic state, which is consistent with our
initial hypothesis.Conclusions
Nearly a century has elapsed since Otto Warburg ob-
served that cancer cells preferentially utilize “aerobic gly-
colysis” (i.e., Warburg metabolism). Recent advances in
understanding the role of CSCs in the propagation and
progression of tumors motivated us to characterize the
metabolic profile of BCSCs. We have demonstrated that
while tumors and benign tissues display similar meta-
bolic profiles, BCSCs and SCs display distinctive profiles.
Moreover, the heterogeneous nature of BCSC subpopu-
lations supports a model of reverse Warburg metabolism
in which nonglycolytic primitive (i.e., stem-like) cells
may be nourished by more mature glycolytic cells in
normoxic conditions. However, when rapidly expanding
tumor cells outgrow their blood supply and the tissue
becomes hypoxic, BCSCs can switch to a proglycocytic
phenotype. The adaptive metabolic abilities of BCSCs
may ensure that tumors can survive the variable condi-
tions encountered during progressive stages of tumor
growth. We propose that coupling inhibitors of hypoxia
and nonglycolytic targets may offer improved therapeutic
response in the treatment of breast cancer via eradication
of cancer stem and progenitor cell populations.
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